[
  {
    "ts": null,
    "headline": "Crispr Therapeutics: Face The Harsh Reality Instead Of Waiting (Rating Downgrade)",
    "summary": "Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high valuation, and speculative pipeline raise concerns.",
    "url": "https://finnhub.io/api/news?id=c2d197414502e2a2e34cce5b8505463d9e7dc8c9bfda7ec1d729e7da4a066333",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750505400,
      "headline": "Crispr Therapeutics: Face The Harsh Reality Instead Of Waiting (Rating Downgrade)",
      "id": 135455322,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316503044/image_1316503044.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high valuation, and speculative pipeline raise concerns.",
      "url": "https://finnhub.io/api/news?id=c2d197414502e2a2e34cce5b8505463d9e7dc8c9bfda7ec1d729e7da4a066333"
    }
  }
]